Data Characteristics for this Category
siRNA nucleic acid drug registration and declaration data originates from diverse sources. These include pharmaceutical research (e.g., sequence design, synthesis processes, quality control), pharmacology and toxicology studies (e.g., in vitro/in vivo activity, safety evaluation), and clinical trial data (e.g., dose escalation, efficacy and safety observations). This data exists in various document formats, such as research reports, experimental records, certificates of analysis, and clinical study protocols and reports. Data update frequency varies significantly across different development stages. Early research stages might see weekly or monthly updates, while clinical trial stages update regularly as trials progress. Documents contain highly specialized fields and units, for example, nucleic acid sequence length (nt), purity (%), endotoxin content (EU/mg), pharmacokinetic parameters (e.g., Cmax, AUC, in ng·h/mL), and clinical safety indicators (e.g., adverse event rates).
Constraints Imposed by These Characteristics on "Workflow Orchestration"
The characteristics of siRNA nucleic acid drug documentation impose specific requirements on workflow orchestration. First, multi-source heterogeneous data formats (PDF, Word, Excel, images, etc.) demand robust document parsing capabilities within the workflow, especially for recognizing tables and embedded charts. Second, the asynchronous nature of data updates necessitates knowledge base construction that supports incremental updates and version management to ensure declaration documents are based on the latest valid data. Third, highly specialized fields and units require precise identification and validation of these specific terms during information extraction and structuring to avoid misinterpretation or omissions. Finally, the strong correlation of interdisciplinary knowledge (e.g., the link between pharmaceutical data and clinical data) means that workflows need to perform multimodal information fusion during knowledge retrieval and generation. For example, evaluating the efficacy of a specific siRNA sequence requires simultaneously linking its pharmaceutical quality indicators and clinical effectiveness data. This demands that the workflow can flexibly call multiple tools or models and integrate their results for comprehensive judgment.
Configuration Settings
| Configuration Item | Suggested Value | Rationale |
|---|---|---|
maxContext | 1200 | siRNA nucleic acid drug declaration document paragraphs often contain dense technical information, requiring a longer context window to capture complete semantics. |
Recall count (Recall Count) | 10 | Considering the complex associations in siRNA pharmacology and toxicology data, increasing the recall count helps cover more potentially relevant information, improving the accuracy of subsequent RAG. |
Similarity threshold (Similarity Threshold) | 0.78 | siRNA sequences and experimental data exhibit high similarity characteristics. A higher threshold helps precisely match content and avoid interference from irrelevant or low-relevance content. |
Rerank result count (Rerank Return Count) | 5 | After recalling multiple documents, reranking filters out the most relevant few items, focusing on core information and reducing the model's processing burden. |
PARSER_MODE | SEMANTIC_CHUNK | The logical structure of siRNA declaration documents is complex. Semantic chunking helps maintain the completeness of each section and reduces context loss. |
TOOL_RESPONSE_TIMEOUT_SECONDS | 600 seconds | Queries for siRNA nucleic acid drug declaration documents may involve complex data retrieval and computation. A longer timeout can accommodate scenarios where tool execution takes a long time. |
Three Common Pitfalls
- Workflow execution times out, showing
Tool execution timed out. This occurs because some siRNA-related data analysis tools (e.g., molecular simulation or bioinformatics analysis) have long execution times, and the default timeout setting is insufficient. - Key parameters (e.g., siRNA purity) in the generated declaration documents are empty or numerically incorrect. This happens when the document parser fails to correctly identify table data in PDF reports, leading to structured information extraction failure.
- The workflow cannot recommend suitable clinical trial protocols based on pharmaceutical data. This is due to insufficient establishment of association relationships between different data types (pharmaceutical, toxicology, clinical) during knowledge base construction, resulting in inadequate multimodal information fusion.
How to Confirm Correct Configuration
- Select an siRNA pharmaceutical research report containing complex tables and charts. Execute the workflow and check if key fields (e.g., nucleic acid sequence, synthesis batch, purity, endotoxin) are accurately extracted in the output structured data.
- Submit a complex query regarding siRNA pharmacology and toxicology. Check if the documents recalled by the workflow cover all relevant research stages and key experimental results, and evaluate if their relevance meets the expected threshold.
- Simulate a query requiring interdisciplinary knowledge fusion, such as "evaluate the liver toxicity of a certain siRNA sequence." Check if the workflow can simultaneously link pharmacology and toxicology reports with clinical safety data and generate a comprehensive answer.
The values provided are common starting points and should be measured against the reader's own samples.
Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.